Ghatge, M., Nair, J., Sharma, A., & Vangala, R. (2018). Integrative gene ontology and network analysis of coronary artery disease associated genes suggests potential role of ErbB pathway gene EGFR. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2018.8393 (Original work published 2018)

Brill, E., Yokoyama, T., Nair, J., Yu, M., Ahn, Y., & Lee, J. (2017). Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer. Oncotarget, 8(67), 111026-111040. https://doi.org/10.18632/oncotarget.22195 (Original work published 2017)

Lee, J., Nair, J., Zimmer, A., Lipkowitz, S., Annunziata, C., Merino, M., … Kohn, E. (2018). Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. The Lancet. Oncology. https://doi.org/10.1016/S1470-2045(18)30009-3 (Original work published 2018)